@article {Zhou54, author = {Ji Zhou and Wenjie You and Guangqiang Sun and Yixuan Li and Bi Chen and Jing Ai and Handong Jiang}, title = {The Marine-Derived Oligosaccharide Sulfate MS80, a Novel Transforming Growth Factor β1 Inhibitor, Reverses Epithelial Mesenchymal Transition Induced by Transforming Growth Factor-β1 and Suppresses Tumor Metastasis}, volume = {359}, number = {1}, pages = {54--61}, year = {2016}, doi = {10.1124/jpet.116.234799}, publisher = {American Society for Pharmacology and Experimental Therapeutics}, abstract = {Metastasis accounts for the majority of cancer-related deaths. Transforming growth factor β (TGF-β) is believed to promote late-stage cancer progression and metastasis by inducing epithelial-mesenchymal transition (EMT). We previously reported that MS80, a novel oligosaccharide sulfate, inhibits TGF-β1{\textendash}induced pulmonary fibrosis by binding TGF-β1. In our study MS80 effectively inhibited TGF-β/Smad signaling in lung cancer cells, breast cancer cells, and model cell lines. In addition, MS80 inhibited TGF-β1{\textendash}induced EMT, motility, and invasion in vitro. Moreover, MS80 significantly inhibited lung metastasis in orthotopic 4T1 xenografts. Notably, the MS80 treatment significantly increased the infiltration of CD8+ T cells and decreased the infiltration of regulatory T cells in primary tumors and spleens in mice bearing 4T1 xenografts. Therefore, MS80 is a novel and promising candidate for treating metastatic malignancies by targeting TGF-β1{\textendash}induced EMT and mediating immunosuppression.}, issn = {0022-3565}, URL = {https://jpet.aspetjournals.org/content/359/1/54}, eprint = {https://jpet.aspetjournals.org/content/359/1/54.full.pdf}, journal = {Journal of Pharmacology and Experimental Therapeutics} }